Related references
Note: Only part of the references are listed.Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105
Yingmiao Liu et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Bevacizumab Alone or in Combination With TRC105 for Patients With Refractory Metastatic Renal Cell Cancer
Tanya B. Dorff et al.
CANCER (2017)
Phase I and Preliminary Phase II Study ofTRC105in Combination with Sorafenib in Hepatocellular Carcinoma
Austin G. Duffy et al.
CLINICAL CANCER RESEARCH (2017)
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
Laura W. Goff et al.
CLINICAL CANCER RESEARCH (2016)
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinomaaEuro
M. Simonelli et al.
ANNALS OF ONCOLOGY (2016)
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207
Paul Wheatley-Price et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
A phase I study of the human anti-activin receptor-like kinase 1 antibody PF-03446962 in Asian patients with advanced solid tumors
Toshihiko Doi et al.
CANCER MEDICINE (2016)
Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
Yingmiao Liu et al.
MOLECULAR CANCER THERAPEUTICS (2015)
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial
A. Necchi et al.
INVESTIGATIONAL NEW DRUGS (2014)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
Christopher H. Lieu et al.
PLOS ONE (2013)
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
Yingmiao Liu et al.
CANCER MEDICINE (2013)
ALK1 as an emerging target for antiangiogenic therapy of cancer
Sara I. Cunha et al.
BLOOD (2011)
Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
Dana D. Hu-Lowe et al.
CANCER RESEARCH (2011)
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours
Ester Fonsatti et al.
CARDIOVASCULAR RESEARCH (2010)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Lymphangiogenesis in development and human disease
K Alitalo et al.
NATURE (2005)
Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism
T Hawighorst et al.
EMBO JOURNAL (2001)
Share Paper
